Defining the margins for errors in patient compliance with prescribed drug regimens

Pharmacoepidemiology and Drug Safety

Volumn 9, Issue 7, 2000, Pages 565-568

  Urquhart, John ^a,b,c,d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Zug   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DOXYCYCLINE; ESTROGEN; FELODIPINE; GESTAGEN; HYDROCHLOROTHIAZIDE; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG HALF LIFE; DRUG MONITORING; DRUG RELEASE; EDITORIAL; ERROR; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REBOUND; RECEPTOR DOWN REGULATION; SIDE EFFECT;

EID: 0034457912     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.540     Document Type: Editorial

References (32)

1. The sixth report of the joint national committee on prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2. Rationale for the use of a fixed combination in the treatment of hypertension
3. The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers
4. A pharmacodynamic assessment of the impact of antihypertensive nonadherence on blood pressure control
5. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens
6. Medication compliance as a feature in drug development
7. The electronic medication event monitor-lessons for pharmacotherapy
8. Enhancing medication compliance for people with serious mental disease
9. Studies on low dose oral contraceptives: Plasma hormone changes in relation to deliberate pill ('MICROGYNON 30') omission
10. 'Escape' ovulation in women due to the missing of low dose combination oral contraceptive pills
11. Hormonal consequences of 'missing the pill'
12. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles
13. The effect of deliberate omission of TRINORDIOL® or MICROGYNON® on the hypothalamo-pituitary-ovarian axis
14. A study design for comparing the effects of missing daily doses of antihypertensive drugs
15. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients
16. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life
17. The effects of missing a dose of enalapril vesus amlodipine on ambulatory blood pressure
18. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
19. On white-coat effects and the electronic monitoring of compliance
20. Any questions
21. Can drug delivery systems delivery value in the new pharmaceutical marketplace?
22. Dose-response and registration of new drugs
23. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
24. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: High therapeutic success rates despite poor compliance
25. Behavioral strategies for long-term survival of transplant recipients
26. Noncompliance may cause half of antihypertensive drug 'failures'